Key Highlights

  • 0.19 is the loss per share analysts project for Eledon Pharmaceuticals (NASDAQ:ELDN), which is slated to release third-quarter 2026 results once trading ends on November 13, 2026, based on screening data.
  • 31.6 million is the USD net loss recorded for Q2 2026, equal to 0.27 per share, compared with 11.2 million and 0.13 twelve months earlier, including a 9.6 million non-cash loss tied to Warrant fair value.
  • 88.8 million is the USD sitting in cash, equivalents plus short-term investments on June 30, 2026, lower than 133.3 million at December 31, 2025, and management says it covers operations into Q2 2027.
  • 600 patients are targeted in the Phase 3 kidney transplant study of tegoprubart, which is expected to begin in late 2026 and to compare against tacrolimus on a 52-week non-inferiority basis.

What Canadian Investors Can Expect From Eledon Pharmaceuticals (NASDAQ:ELDN) on November 13, 2026

Eledon Pharmaceuticals is scheduled to release third-quarter 2026 numbers once the market has closed (AMC) on November 13, 2026. Based on snapshot data from the screener, analysts expect a loss of 0.19 per share, with a valuation for the company of USD 216.97 million. As reference points, the Q2 loss was 0.27 per share, while the third-quarter 2025 loss was 0.21 per share, with USD 17.5 million lost overall. Shifts in warrant Fair Value can swing headline figures sharply between periods.

The Rationale: Latest Quarter and Management Commentary for Eledon Pharmaceuticals (NASDAQ:ELDN)

During Q2 2026 Research and Development spending reached USD 18.2 million against USD 20.3 million a year before, administrative overhead was USD 4.6 million, and overall operating costs came to USD 22.9 million. Setting aside warrant movements, the loss was USD 22.0 million. Management highlighted BESTOW results at 18 months showing a mean eGFR near 74 versus 61 for tacrolimus, no acute rejection events confirmed by biopsy for tegoprubart recipients beyond six months compared with seven events (9.4%) on tacrolimus, and 12 of 12 islet patients free of insulin. Management offered no official outlook for finances.

Valuation, Liquidity and Risks for Eledon Pharmaceuticals (NASDAQ:ELDN)

According to the screener, the company is valued at USD 216.97 million. Liquid holdings of USD 88.8 million compare to USD 93.4 million on September 30, 2025. Warrant liabilities climbed to USD 40.0 million from USD 11.4 million at the end of last year, and 80,891,404 common shares were outstanding. Because Eledon is a clinical-stage Business with no product sales located in public coverage, it carries trial, regulatory and funding risk, and the Phase 3 launch plus any fresh Capital raise might dilute shareholders. The P/E ratio carries no meaning given the losses.

Where Things Stand

Eledon Pharmaceuticals (NASDAQ:ELDN) will release third-quarter 2026 results once trading ends on November 13, 2026, with analysts expecting a 0.19 loss for each share and the company valued at USD 216.97 million, based on screener data. The Q2 net loss totalled USD 31.6 million, cash was USD 88.8 million and management pointed to funding that lasts into Q2 2027. Readers should watch for news on the 600-patient Phase 3 kidney transplant study planned for late 2026, islet-cell and liver transplant programs, xenotransplantation commentary and financing intentions. This piece is informational only.